Join

Compare · BHSE vs GILD

BHSE vs GILD

Side-by-side comparison of Bull Horn Holdings Corp. (BHSE) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BHSE and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • GILD is the larger of the two at $161.88B, about 1725.0x BHSE ($93.8M).
  • GILD has hit the wire 8 times in the past 4 weeks while BHSE has been quiet.
  • GILD has more recent analyst coverage (25 ratings vs 0 for BHSE).
MetricBHSEGILD
Company
Bull Horn Holdings Corp.
Gilead Sciences Inc.
Price
$12.50+50.42%
$130.38-2.48%
Market cap
$93.8M
$161.88B
1M return
-
-5.67%
1Y return
-
+22.62%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2020
1992
News (4w)
0
8
Recent ratings
0
25
BHSE

Bull Horn Holdings Corp.

Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.

GILD

Gilead Sciences Inc.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Latest BHSE

Latest GILD